Placeholder image

Overview

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start  a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in 2021.

Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in 2021.

Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction.

Other preclinical programs include: 

  • GABAB PAM for CMT1A 
  • mGlu7 NAM for PTSD 
  • mGlu2 NAM for mild neurocognitive disorders 
  • mGlu4 PAM for Parkinson’s disease  
  • mGlu3 PAM for neurodegenerative disorders 

Addex was founded in 2002, headquartered in Geneva, Switzerland and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN since 2007, and on the NASDAQ exchange also under the trading symbol ADXN since 2020.  

Find out more about ouClinical and Pre-Clinical Pipeline.